120 related articles for article (PubMed ID: 11340577)
1. Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant.
Watanabe T; Shinohara N; Sazawa A; Takimoto M; Hashimoto A; Koyanagi T; Kuzumaki N
Int J Cancer; 2001 Jun; 92(5):712-7. PubMed ID: 11340577
[TBL] [Abstract][Full Text] [Related]
2. Suppression of Erk activation and in vivo growth in esophageal cancer cells by the dominant negative Ras mutant, N116Y.
Senmaru N; Shichinohe T; Takeuchi M; Miyamoto M; Sazawa A; Ogiso Y; Takahashi T; Okushiba S; Takimoto M; Kato H; Kuzumaki N
Int J Cancer; 1998 Oct; 78(3):366-71. PubMed ID: 9766573
[TBL] [Abstract][Full Text] [Related]
3. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice.
Takeuchi M; Shichinohe T; Senmaru N; Miyamoto M; Fujita H; Takimoto M; Kondo S; Katoh H; Kuzumaki N
Gene Ther; 2000 Mar; 7(6):518-26. PubMed ID: 10757026
[TBL] [Abstract][Full Text] [Related]
4. Suppressive effects of dominant negative ras mutant N116Y on transformed phenotypes of human bladder cancer cells.
Watanabe T; Shinohara N; Sazawa A; Kobayashi Y; Ogiso Y; Kimura T; Takiguchi M; Yasuda J; Hashimoto A; Koyanagi T; Kuzumaki N
Cancer Lett; 2000 Feb; 149(1-2):195-202. PubMed ID: 10737724
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice.
Sazawa A; Watanabe T; Tanaka M; Haga K; Fujita H; Harabayashi T; Shinohara N; Koyanagi T; Kuzumaki N
J Urol; 2002 Sep; 168(3):1182-7. PubMed ID: 12187264
[TBL] [Abstract][Full Text] [Related]
6. Suppression of various human tumor cell lines by a dominant negative H-ras mutant.
Ogiso Y; Sakai N; Watari H; Yokoyama T; Kuzumaki N
Gene Ther; 1994 Nov; 1(6):403-7. PubMed ID: 7584106
[TBL] [Abstract][Full Text] [Related]
7. Suppression of pancreatic cancer by the dominant negative ras mutant, N116Y.
Shichinohe T; Senmaru N; Furuuchi K; Ogiso Y; Ishikura H; Yoshiki T; Takahashi T; Kato H; Kuzumaki N
J Surg Res; 1996 Dec; 66(2):125-30. PubMed ID: 9024823
[TBL] [Abstract][Full Text] [Related]
8. Suppressive effect of modified dominant negative RAS mutant on human cancer by gene transfer with non-viral vector.
Suzuki H; Kuzumaki S; Nakagawa K; Takimoto M; Shichinohe T
Cancer Biol Ther; 2006 Nov; 5(11):1487-91. PubMed ID: 17102594
[TBL] [Abstract][Full Text] [Related]
9. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.
Watanabe T; Shinohara N; Sazawa A; Harabayashi T; Ogiso Y; Koyanagi T; Takiguchi M; Hashimoto A; Kuzumaki N; Yamashita M; Tanaka M; Grossman HB; Benedict WF
Cancer Gene Ther; 2000 Dec; 7(12):1575-80. PubMed ID: 11228536
[TBL] [Abstract][Full Text] [Related]
10. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
Yokoyama T
Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer.
Irie A; Anderegg B; Kashani-Sabet M; Ohkawa T; Suzuki T; Halks-Miller M; Curiel DT; Scanlon KJ
Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):341-9. PubMed ID: 10463078
[TBL] [Abstract][Full Text] [Related]
12. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo.
Mühlhauser J; Merrill MJ; Pili R; Maeda H; Bacic M; Bewig B; Passaniti A; Edwards NA; Crystal RG; Capogrossi MC
Circ Res; 1995 Dec; 77(6):1077-86. PubMed ID: 7586219
[TBL] [Abstract][Full Text] [Related]
13. In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer.
Sutton MA; Freund CT; Berkman SA; Dang TD; Kattan MW; Wheeler TM; Rowley DR; Lerner SP
Mol Ther; 2000 Sep; 2(3):211-7. PubMed ID: 10985951
[TBL] [Abstract][Full Text] [Related]
14. Suppression of human colon tumor growth by adenoviral vector-mediated NK4 expression in an athymic mouse model.
Jie JZ; Wang JW; Qu JG; Hung T
World J Gastroenterol; 2007 Apr; 13(13):1938-46. PubMed ID: 17461494
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo.
Cirielli C; Riccioni T; Yang C; Pili R; Gloe T; Chang J; Inyaku K; Passaniti A; Capogrossi MC
Int J Cancer; 1995 Nov; 63(5):673-9. PubMed ID: 7591284
[TBL] [Abstract][Full Text] [Related]
16. Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model.
Tanaka T; Shimura H; Sasaki T; Narumi K; Maemondo M; Nukiwa T; Matsumoto K; Nakamura T; Ikeda S
Cancer Gene Ther; 2004 Jun; 11(6):431-40. PubMed ID: 15118756
[TBL] [Abstract][Full Text] [Related]
17. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
[TBL] [Abstract][Full Text] [Related]
18. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated gene transfer of P16INK4/CDKN2 into bax-negative colon cancer cells induces apoptosis and tumor regression in vivo.
Tamm I; Schumacher A; Karawajew L; Ruppert V; Arnold W; Nüssler AK; Neuhaus P; Dörken B; Wolff G
Cancer Gene Ther; 2002 Aug; 9(8):641-50. PubMed ID: 12136424
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitization of human glioma cells in vitro and in vivo with acyclovir and mutant HSV-TK75 expressed from adenovirus.
Rosenberg E; Hawkins W; Holmes M; Amir C; Schmidt-Ullrich RK; Lin PS; Valerie K
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):831-6. PubMed ID: 11849808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
